GLJ Research Recommends Adding to Tilray (TLRY) Short into Q3 Earnings Season

October 10, 2019 9:38 AM EDT
Get Alerts TLRY Hot Sheet
Price: $12.17 +1.33%

Rating Summary:
    4 Buy, 15 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

GLJ Research analyst Gordon Johnson reiterated a Sell rating and $7.00 price target on Tilray (NASDAQ: TLRY) saying they would be adding to short positions into Q3 earnings season or the Canadian cannabis industry.

Johnson commented, "As we warned in our 10/7/19 note titled: “CANNABIS INDUSTRY UPDATE: Are Canadian Provinces the "Big Bad Wolf" to Canadian Cannabis Companies?”, we expect C3Q19 earnings from the bevy of publicly listed Canadian cannabis companies to be (large) downside catalyst(s). We reiterate our (very) negative bias on TLRY, SELL rating, and $7/shr 2020 year-end price objective (-71% downside from yesterday’s closing price). At risk of stating the obvious, we would be adding to the TLRY short ahead of C3Q19 Canadian cannabis earnings season."

The analyst highlighted that HEXO (NYSE: HEXO) cut its Q3 guidance by 40% and withdrew its FY20 outlook.

For an analyst ratings summary and ratings history on Tilray click here. For more ratings news on Tilray click here.

Shares of Tilray closed at $23.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Short Sales, Trader Talk

Related Entities

Earnings, Gordon Johnson